Welcome to our dedicated page for Adagio Medical SEC filings (Ticker: ADGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adagio Medical Holdings, Inc. filings document a public medical-device issuer developing catheter ablation systems for cardiac arrhythmias. Its Form 8-K reports include operating and financial results, business updates, clinical-study announcements, FDA IDE-related events, and press releases concerning the vCLAS® Ventricular Ablation System and Ultra-Low Temperature Ablation technology.
The company’s proxy and governance filings cover shareholder voting matters, director nominations, annual-meeting results, material agreements, governance practices, and capital-structure disclosures. Filings also identify ADGM common stock as Nasdaq-listed and classify the company as an emerging growth company for Exchange Act reporting purposes.
RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah filed an amendment to a Schedule 13G regarding Adagio Medical Holdings, Inc. The filing states that each Reporting Person beneficially owns 0 shares of Adagio common stock, representing 0.0% of the class as of June 30, 2025. The Reporting Persons expressly disclaim being a group and confirm the shares were not acquired to influence control of the issuer.
Adagio Medical Holdings furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business update; the release is attached as Exhibit 99.1.
The company also updated its corporate presentation for investor and analyst use, made available on its website and attached as Exhibit 99.2. Both items are expressly stated as furnished (not filed) under the Exchange Act.
Adage Capital Management, L.P., together with individuals Robert Atchinson and Phillip Gross, reported beneficial ownership of 821,261 shares of Adagio Medical Holdings, Inc. common stock, representing 5.34% of the class. The percentage was calculated using 15,381,565 shares outstanding as of May 7, 2025, per the company quarterly report filed May 15, 2025. The Schedule 13G shows shared voting and shared dispositive power over all 821,261 shares and includes a certification that the securities were acquired and are held in the ordinary course of business and not to influence control. The filing lists the issuer office in Laguna Hills, CA, and includes a joint filing agreement as Exhibit 99.1.